6UF0 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)366.00
Market Cap
€1.36M
Enterprise Value€2.73
Total Cash (Recent Filing)€37.43K
Total Debt (Recent Filing)€1.27M
Price to Earnings (P/E)―
Beta-2.11
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding108,819,870
10 Day Avg. Volume600
30 Day Avg. Volume366
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash BurnLower cash outflows than in prior years indicate tighter spending and may extend the company’s operating runway. However, this remains only a relative improvement: operating cash flow and free cash flow are still negative, so the business has not yet reached self-funding.
Narrower LossesThe reduction in losses suggests some progress in cost control or reduced operating commitments compared with the 2021 baseline. This can lessen funding needs over time, although persistent EBIT and net losses mean the improvement has not yet produced profitability or operating momentum.
Higher Asset BaseA larger asset base provides more resources than were available at the very low March 2025 level and may support ongoing development activities. The benefit is limited, however, because the balance sheet remains weak and debt exceeds total assets in the latest period.
Bears Say
No Revenue BaseZero reported revenue across the periods provided means the company has not demonstrated a commercial operating base or recurring customer demand. Persistent operating losses leave future progress dependent on development success, financing, and cost control rather than established revenue generation.
Negative Equity And High LeverageNegative shareholders’ equity and debt greater than total assets signal a strained capital structure and materially reduce financial flexibility. This weak solvency position can constrain investment capacity and make continued operations more dependent on external financing or balance-sheet restructuring.
Ongoing Cash ConsumptionContinued negative operating and free cash flow shows that the company remains a net cash user and cannot currently fund operations internally. Even with lower burn than earlier years, ongoing cash consumption increases reliance on financing and limits resilience if funding becomes less available.
NeonMind Biosciences Inc News
6UF0 FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is €1.36M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Nov 27, 2026 which is in 80 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Aug 01, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 108,819,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in DE:6UF0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine project, located in Lordsburg, New Mexico, in the United States. The firm's headquarters are situated in West Vancouver, Canada.